Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

of marketing authorization approval from the European Commission for the use of pirfenidone for the treatment of IPF and the expected timing thereof, statements regarding commercial launch preparations and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, (i) whether the European Commission approves the marketing authorization for pirfenidone for the treatment of IPF and the actual timing of the decision; (ii) risks related to unexpected regulatory actions or delays or government regulation generally; (iii) risks related to the clinical and regulatory process for pirfenidone, including having no unexpected safety, toxicology, clinical or other issues; (iv) unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; (v) government, industry and general public pricing pressures; (vi) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections; (vii) risks related to building the infrastructure required for commercial launch in various countries in the European Union, and (viii) those other factors discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2010 (the "Form 10-K"), and other periodic reports filed with the SEC.  The risks and other factors discussed above should be considered only
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... FRANCISCO , Jan. 13 Today, endpoint ( ... users to design and deploy clinical trial IRT systems in ... Leveraging a background of more than 12 years designing Integrated ... designed PULSE to balance speed of deployment with flawless quality. ...
... ROCHESTER, N.Y. , Jan. 12 After a decade of ... decelerated and may have even fallen when adjusted for inflation.  That is ... the American Medical Association .   , "The era of rapid expansion ... Ray Dorsey , M.D. , a neurologist at the ...
... , ... Institute announces twenty-four exhibitors to showcase new products at the 17th Molecular Medicine Tri-Conference, ... Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating ... ...
Cached Biology Technology:endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 2A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 3A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 4
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... for spinal cord injury (SCI), traumatic brain injury (TBI) ... deal has been learned over the past 30 years ... that regulate axon growth, but this large body of ... Prof. Lemmon and his team from University of Miami ... causes, but a consensus is emerging that one contributing ...
(Date:7/30/2014)... , July 30, 2014 The Nano-Bio ... United States Air Force Research Laboratory (AFRL), has ... Binghamton University to develop electronics ... (HPM). The $425,000 project, with contributions from the ... i3 Electronics, Inc. ( Endicott, N.Y. ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... $50 million to a multi-institution collaborative headquartered at the ... cyberinfrastructure for the biological sciences. The renewal ... the Texas Advanced Computing Center (TACC) at the University ... New York, and University of North Carolina Wilmington (UNCW), ...
... Researchers have discovered why multiple myeloma, a difficult to cure ... effective treatment that can keep the disease at bay for ... colleagues at Princess Margaret Hospital in Toronto, researchers from Mayo ... in Phoenix were part of the team that conducted the ...
... NEW YORK , Sept. 18, 2013 ... research report is available in its catalogue: ... Global Biometrics Market ... the Market Grow Manifold,This study analyzes the ...
Cached Biology News:$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 2$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 3$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 4Research team uncovers root cause of multiple myeloma relapse 2Emerging Opportunities in Global Biometrics Market 2Emerging Opportunities in Global Biometrics Market 3Emerging Opportunities in Global Biometrics Market 4Emerging Opportunities in Global Biometrics Market 5
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: